Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Riether, Carsten  [Clear All Filters]
2013
Schürch CM, Riether C, Ochsenbein AF. Dendritic Cell-Based Immunotherapy for Myeloid Leukemias. Front Immunol. 2013;4:496.
2015
Mager LF, Riether C, Schürch CM, Banz Y, Wasmer M-H, Stuber R, Theocharides AP, Li X, Xia Y, Saito H, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015.
2019
Radpour R, Riether C, Simillion C, Höpner S, Bruggmann R, Ochsenbein AF. CD8 T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. Leukemia. 2019.
2021
Riether C, Radpour R, Kallen NM, Bürgin DT, Bachmann C, Schürch CM, Lüthi U, Arambasic M, Hoppe S, Albers CE, et al. Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. Cell Rep. 2021;34(4):108663.
Hinterbrandner M, Rubino V, Stoll C, Forster S, Schnüriger N, Radpour R, Baerlocher GM, Ochsenbein AF, Riether C. Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. JCI Insight. 2021.
2023
Naef P, Radpour R, Jaeger-Ruckstuhl CA, Bodmer N, Baerlocher GM, Doehner H, Doehner K, Riether C, Ochsenbein AF. IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways. Sci Signal. 2023;16(800):eadd7705.